Atypical case of Wolfram syndrome revealed through targeted exome sequencing in a patient with suspected mitochondrial disease
- Daniel S Lieber†1, 2, 3, 4,
- Scott B Vafai†1, 2, 3, 4, 5,
- Laura C Horton6,
- Nancy G Slate1, 2,
- Shangtao Liu1, 2,
- Mark L Borowsky1, 4,
- Sarah E Calvo1, 2, 3, 4,
- Jeremy D Schmahmann6Email author and
- Vamsi K Mootha1, 2, 3, 4Email author
© Lieber et al; licensee BioMed Central Ltd. 2012
Received: 6 September 2011
Accepted: 6 January 2012
Published: 6 January 2012
Mitochondrial diseases comprise a diverse set of clinical disorders that affect multiple organ systems with varying severity and age of onset. Due to their clinical and genetic heterogeneity, these diseases are difficult to diagnose. We have developed a targeted exome sequencing approach to improve our ability to properly diagnose mitochondrial diseases and apply it here to an individual patient. Our method targets mitochondrial DNA (mtDNA) and the exons of 1,600 nuclear genes involved in mitochondrial biology or Mendelian disorders with multi-system phenotypes, thereby allowing for simultaneous evaluation of multiple disease loci.
Targeted exome sequencing was performed on a patient initially suspected to have a mitochondrial disorder. The patient presented with diabetes mellitus, diffuse brain atrophy, autonomic neuropathy, optic nerve atrophy, and a severe amnestic syndrome. Further work-up revealed multiple heteroplasmic mtDNA deletions as well as profound thiamine deficiency without a clear nutritional cause. Targeted exome sequencing revealed a homozygous c.1672C > T (p.R558C) missense mutation in exon 8 of WFS1 that has previously been reported in a patient with Wolfram syndrome.
This case demonstrates how clinical application of next-generation sequencing technology can enhance the diagnosis of patients suspected to have rare genetic disorders. Furthermore, the finding of unexplained thiamine deficiency in a patient with Wolfram syndrome suggests a potential link between WFS1 biology and thiamine metabolism that has implications for the clinical management of Wolfram syndrome patients.
Mitochondrial diseases are a clinically heterogeneous set of disorders that are caused by defects in mitochondria, the organelles responsible for producing most of the cellular ATP in humans . Multiple organ-systems are typically affected in these disorders, with neurologic and myopathic features being the most prominent . Common clinical features of mitochondrial disease include skeletal myopathy accompanied by exercise intolerance, cardiomyopathy, sensorimotor peripheral polyneuropathy, sensorineural deafness, optic atrophy, diabetes mellitus, seizures, and ataxia . These disorders can be caused by mutations in the nuclear or mitochondrial genomes, and over 100 loci have been identified to date .
The clinical and genetic heterogeneity of mitochondrial diseases as well as the technical difficulty of assessing mitochondrial function create a significant diagnostic challenge . One major source of cost and time delays in the clinical evaluation of patients with suspected mitochondrial disease is the use of sequential genetic tests to evaluate individual disorders; as such, a systematic genetic test could accelerate the diagnostic process and reduce overall cost. In the present report, we describe a suspected case of mitochondrial disease whose diagnosis of Wolfram syndrome was ultimately revealed through targeted exome sequencing.
In January 2008, a 61-year-old man with a history notable for diabetes mellitus (DM), autonomic neuropathy, diffuse brain atrophy, optic nerve atrophy (OA), and profound amnesia was referred to us to establish neurologic care. The patient carried a diagnosis of multiple system atrophy- cerebellar type (MSAc), principally because of severe cerebellar and brainstem atrophy on MRI.
The patient's early history was remarkable only for childhood bedwetting and urinary urgency as a young adult. He was otherwise well during this time and was a talented athlete who completed college and practiced as an accountant. In his early 20s, he developed bladder dysfunction of unclear etiology requiring intermittent straight catheterization, as well as erectile dysfunction.
At age 33, he was diagnosed with DM, presumed to be type 1, and began treatment with insulin therapy. Although there is no biochemical data available from the time of his original diagnosis, recent testing demonstrated a random C-peptide level of 0.6 ng/mL (reference range 0.9 to 4.3 ng/mL) at a time when his blood glucose was 83 mg/dL. He takes an average of 24 units of insulin per day, and has had good glycemic control with hemoglobin A1c measurements ranging between 6.5 and 7.2% over the last several years. He has had no evidence of retinopathy, or other microvascular or macrovascular complications. He had polyuria and polydipsia at the time of his initial DM diagnosis, but these symptoms resolved once he initiated insulin therapy.
During his late 50s, the patient's neurologic status deteriorated. Formal neuropsychological evaluation revealed profound anterograde amnesia, with additional impairments in cognitive flexibility, executive function, naming, and high order visual processing skills. Attention span, mental tracking, verbal abstract reasoning, complex auditory instructions, and visual spatial functions were preserved. From a psychiatric perspective, he developed symptoms of depression, which responded to treatment with sertraline.
In parallel with the decline in his memory, the patient also developed progressive autonomic neuropathy, with gastroparesis and severe postural hypotension. The autonomic dysfunction exceeded what might be expected from his diabetes mellitus, given his good glycemic control and the absence of other diabetic complications. His bladder dysfunction worsened and he required suprapubic catheter placement at the age of 61. Due to his multiple functional deficits, the patient became unable to work and is now completely reliant upon his wife for care.
Regarding his family history, the patient was born to Ashkenazi Jewish parents and there was no parental consanguinity. His mother died from melanoma, and his father died from multiple strokes and a myocardial infarction. He has two adult daughters, one of whom has attention deficit hyperactivity disorder (ADHD) and Tourette syndrome, while the other suffers from chronic urinary tract infections. His maternal grandmother had type 2 DM, and a maternal first cousin had type 1 DM. No other close relatives have suffered from endocrine, psychiatric, or neurologic disease.
The absence of the cerebellar motor syndrome and the presence of a profound amnestic syndrome on examination called the patient's diagnosis of MSAc into question , and we undertook re-evaluation of his case to explore alternate diagnoses. His laboratory work-up revealed an undetectable thiamine level, a surprising finding given his normal diet and the absence of alcohol abuse. We ascribed his amnestic disorder to presumed long-standing thiamine deficiency, but repletion produced minimal clinical impact. The involvement of multiple systems suggested the possibility of a mitochondrial disorder. Genetic testing for OPA1, MELAS, MERFF, LHON and NARP were negative, however analysis of mitochondrial DNA (mtDNA) from a muscle biopsy sample by both Southern blotting and PCR analysis revealed multiple heteroplasmic deletions. Biochemical testing revealed a minor defect in complex I of the electron transport chain. COX and SDH staining of the muscle biopsy specimen were unremarkable, and the mitochondria appeared grossly normal on electron microscopic examination. Occasional central vacuoles and tubular aggregates were seen in the myocytes, which were felt to be consistent with a mild non-specific myopathy.
Discussion and Conclusions
Wolfram syndrome (OMIM #222300) is an autosomal recessive disorder also known as DIDMOAD for its typical clinical features of Diabetes Insipidus, Diabetes Mellitus, Optic Atrophy and Deafness . The minimum criteria for the diagnosis of Wolfram syndrome are the presence of diabetes mellitus and optic atrophy, both of which usually occur by the age of fifteen . The disorder is also associated with diverse neurologic and psychiatric symptoms, including cognitive impairment . Though with genetic data in hand the diagnosis of Wolfram syndrome now seems clear for the patient presented here, his late age of onset and the prominence of his amnesia are quite atypical for this syndrome and made the diagnosis seem less likely. Furthermore, the clinical presentation, mtDNA deletions, and biochemical data were highly suggestive of a mitochondrial disorder.
Given the multiple organ system dysfunction characteristic of Wolfram syndrome, it was initially thought by a number of clinicians to be a bona fide mitochondrial disorder . Further supporting this hypothesis was the observation of mtDNA deletions in some patients with Wolfram syndrome [14–16]. However, in 1998 two groups identified WFS1, which encodes an 890 amino acid trans-membrane protein localized to the endoplasmic reticulum, as the gene responsible for the majority of Wolfram syndrome cases, thereby arguing against a mitochondrial etiology [17, 18]. Mechanistic studies of WFS1 have revealed an important role in dampening the ER stress response in pancreatic beta cells and neurons, and loss of the gene has been shown to result in an exaggerated stress response and accelerated cell death . However, given the shared clinical features between Wolfram syndrome and many mitochondrial disorders, as well as the presence of mtDNA deletions in some patients, many unanswered questions remain about the biology of WFS1 and its impact on mitochondrial function and mtDNA maintenance.
Mutations in residue 558 of WFS1, as identified in the patient described here, have been previously reported. Our patient's p.R558C mutation was first reported as a heterozygous variant in a cohort of psychiatric patients, though it is unclear whether the variant contributed to disease pathogenesis in that population . Our patient's p.R558C mutation, as well as a p.R558H mutation, have been reported in multiple patients with Wolfram syndrome [9, 21, 22]. Exome databases suggest that the allele frequency of WFS1 c.1672C > T (p.R558C) is quite rare; specifically, the variant is not found in the 1,000 Genomes Project  nor in over 2,500 publicly available European and African American exomes .
Chaussenot et al. specifically discuss the phenotype of a Wolfram case with the same p.R558C mutation identified in our patient in compound heterozygosity with a p.F354del frameshift mutation . Like our patient, Chaussenot et al.'s case had significant cerebellar atrophy by MRI, neurogenic bladder symptoms, dementia, DM, OA, as well as the absence of diabetes insipidus. However, unlike our patient, the compound heterozygote case had earlier onset of DM, OA, and neurologic symptoms (at ages 9, 10, and 27 respectively), lacked hearing impairment, and developed cerebellar ataxia and nystagmus as part of her neurologic presentation. Of note, the profound amnestic syndrome seen in our patient was not reported for the compound heterozygote case, and is atypical for Wolfram syndrome patients in general. These cases demonstrate that phenotypic heterogeneity is present even among patients with similar mutations, likely attributable to different genetic and environmental backgrounds.
Some WFS1 mutations have been suggested to function in an autosomal dominant manner yielding symptoms such as optic atrophy and hearing impairment in a heterozygous state [25, 26]. The patient has one daughter who struggled with Tourette syndrome and ADHD, but the family history is otherwise unremarkable, with no close family members suffering from symptoms associated with Wolfram syndrome. No familial DNA was available to determine the carrier status of his daughter. It is unlikely that his daughter's symptoms are related to WFS1, and we suspect that the p.R558C variant likely acts in a recessive manner.
One of the most striking aspects of the case presented here is the profound thiamine deficiency, and its devastating impact on the patient's memory. The symptom complex of diabetes mellitus, deafness, and optic atrophy has been found in association with defects in thiamine metabolism previously in the context of thiamine-responsive megaloblastic anemia syndrome, or Rogers syndrome (OMIM # 249270) [27–29]. Rogers syndrome, a recessive condition caused by mutations in the thiamine transporter SLC19A2, is characterized by thiamine-responsive megaloblastic anemia, sensorineural deafness, and DM; its phenotypic similarity to Wolfram syndrome suggests the possibility that disruption of thiamine metabolism may contribute to the pathophysiology of Wolfram syndrome. The coding exons of SLC19A2 were sequenced in our patient and no rare mutations were detected, although the presence of non-coding variants cannot be excluded. Given that there was no dietary reason for our patient to develop thiamine deficiency, his case suggests that WFS1 may impact thiamine transport or utilization. Furthermore, given that there are no therapies available for the treatment of Wolfram syndrome, assessment of thiamine sufficiency and possibly empiric thiamine supplementation should be considered for these patients.
The patient presented here had a diagnostic journey that is not unusual for disorders involving dysfunction across multiple organ systems, in that several years elapsed and numerous costly genetic tests were performed without a molecular diagnosis. The application of MitoExome sequencing in this case illustrates how clinical application of next-generation sequencing technology can allow for rapid, simultaneous evaluation for multiple genetic disorders with a single test thereby accelerating the diagnostic process. Furthermore, this case demonstrates how careful study of an individual patient with a rare disorder can yield potentially new insight into gene function and disease pathogenesis.
Written informed consent was obtained from the patient and his wife for publication of this case report.
List of abbreviations
Magnetic Resonance Imaging
multiple system atrophy, cerebellar-type
attention deficit hyperactivity disorder.
This research was supported by NIH/NHGRI grant RC2HG005556 (VKM), NIH/NIDDK grant T32 DK007028-37 (SBV), an NSF Graduate Research Fellowship Program grant (DSL), and the MINDlink and Birmingham Foundations (JDS). The authors would like to thank Molly Plovanich and Dr. Joseph Avruch for comments on the manuscript.
- Calvo SE, Mootha VK: The mitochondrial proteome and human disease. Annu Rev Genomics Hum Genet. 2010, 11: 25-44. 10.1146/annurev-genom-082509-141720.View ArticlePubMedPubMed CentralGoogle Scholar
- Morava E, van den Heuvel L, Hol F, de Vries MC, Hogeveen M, Rodenburg RJ, Smeitink JA: Mitochondrial disease criteria: diagnostic applications in children. Neurology. 2006, 67 (10): 1823-1826. 10.1212/01.wnl.0000244435.27645.54.View ArticlePubMedGoogle Scholar
- Chinnery PF: Mitochondrial Disorders Overview. Gene Reviews at GeneTests: Medical Genetics Information Resource (database online). 2010, Copyright, University of Washington, Seattle, 1997-2011. Available at http://www.genetests.org. Accessed October 2011Google Scholar
- Tucker EJ, Compton AG, Thorburn DR: Recent advances in the genetics of mitochondrial encephalopathies. Curr Neurol Neurosci Rep. 10 (4): 277-285.
- Bernier FP, Boneh A, Dennett X, Chow CW, Cleary MA, Thorburn DR: Diagnostic criteria for respiratory chain disorders in adults and children. Neurology. 2002, 59 (9): 1406-1411.View ArticlePubMedGoogle Scholar
- Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, Wood NW, Colosimo C, Durr A, Fowler CJ, et al: Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008, 71 (9): 670-676. 10.1212/01.wnl.0000324625.00404.15.View ArticlePubMedPubMed CentralGoogle Scholar
- Gnirke A, Melnikov A, Maguire J, Rogov P, LeProust EM, Brockman W, Fennell T, Giannoukos G, Fisher S, Russ C, et al: Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat Biotechnol. 2009, 27 (2): 182-189. 10.1038/nbt.1523.View ArticlePubMedPubMed CentralGoogle Scholar
- Froissart R, Guffon N, Vanier MT, Desnick RJ, Maire I: Fabry disease: D313Y is an alpha-galactosidase A sequence variant that causes pseudodeficient activity in plasma. Mol Genet Metab. 2003, 80 (3): 307-314. 10.1016/S1096-7192(03)00136-7.View ArticlePubMedGoogle Scholar
- Cano A, Rouzier C, Monnot S, Chabrol B, Conrath J, Lecomte P, Delobel B, Boileau P, Valero R, Procaccio V, et al: Identification of novel mutations in WFS1 and genotype-phenotype correlation in Wolfram syndrome. Am J Med Genet A. 2007, 143A (14): 1605-1612. 10.1002/ajmg.a.31809.View ArticlePubMedGoogle Scholar
- Tranebjaerg L, Barrett T, Rendtorff ND: WFS1-Related Disorders. Gene Reviews at GeneTests: Medical Genetics Information Resource (database online). 2009, Copyright, University of Washington, Seattle, 1997-2011. Available at http://www.genetests.org. Accessed October 2011Google Scholar
- Rigoli L, Lombardo F, Di Bella C: Wolfram syndrome and WFS1 gene. Clin Genet. 2011, 79 (2): 103-117. 10.1111/j.1399-0004.2010.01522.x.View ArticlePubMedGoogle Scholar
- Chaussenot A, Bannwarth S, Rouzier C, Vialettes B, Mkadem SA, Chabrol B, Cano A, Labauge P, Paquis-Flucklinger V: Neurologic features and genotype-phenotype correlation in Wolfram syndrome. Ann Neurol. 2011, 69 (3): 501-508. 10.1002/ana.22160.View ArticlePubMedGoogle Scholar
- Bu X, Rotter JI: Wolfram syndrome: a mitochondrial-mediated disorder?. Lancet. 1993, 342 (8871): 598-600. 10.1016/0140-6736(93)91416-J.View ArticlePubMedGoogle Scholar
- Rotig A, Cormier V, Chatelain P, Francois R, Saudubray JM, Rustin P, Munnich A: Deletion of mitochondrial DNA in a case of early-onset diabetes mellitus, optic atrophy, and deafness (Wolfram syndrome, MIM 222300). J Clin Invest. 1993, 91 (3): 1095-1098. 10.1172/JCI116267.View ArticlePubMedPubMed CentralGoogle Scholar
- Barrientos A, Casademont J, Saiz A, Cardellach F, Volpini V, Solans A, Tolosa E, Urbano-Marquez A, Estivill X, Nunes V: Autosomal recessive Wolfram syndrome associated with an 8.5-kb mtDNA single deletion. Am J Hum Genet. 1996, 58 (5): 963-970.PubMedPubMed CentralGoogle Scholar
- Barrientos A, Volpini V, Casademont J, Genis D, Manzanares JM, Ferrer I, Corral J, Cardellach F, Urbano-Marquez A, Estivill X, et al: A nuclear defect in the 4p16 region predisposes to multiple mitochondrial DNA deletions in families with Wolfram syndrome. J Clin Invest. 1996, 97 (7): 1570-1576. 10.1172/JCI118581.View ArticlePubMedPubMed CentralGoogle Scholar
- Strom TM, Hortnagel K, Hofmann S, Gekeler F, Scharfe C, Rabl W, Gerbitz KD, Meitinger T: Diabetes insipidus, diabetes mellitus, optic atrophy and deafness (DIDMOAD) caused by mutations in a novel gene (wolframin) coding for a predicted transmembrane protein. Hum Mol Genet. 1998, 7 (13): 2021-2028. 10.1093/hmg/7.13.2021.View ArticlePubMedGoogle Scholar
- Inoue H, Tanizawa Y, Wasson J, Behn P, Kalidas K, Bernal-Mizrachi E, Mueckler M, Marshall H, Donis-Keller H, Crock P, et al: A gene encoding a transmembrane protein is mutated in patients with diabetes mellitus and optic atrophy (Wolfram syndrome). Nat Genet. 1998, 20 (2): 143-148. 10.1038/2441.View ArticlePubMedGoogle Scholar
- Fonseca SG, Ishigaki S, Oslowski CM, Lu S, Lipson KL, Ghosh R, Hayashi E, Ishihara H, Oka Y, Permutt MA, et al: Wolfram syndrome 1 gene negatively regulates ER stress signaling in rodent and human cells. J Clin Invest. 2010, 120 (3): 744-755. 10.1172/JCI39678.View ArticlePubMedPubMed CentralGoogle Scholar
- Torres R, Leroy E, Hu X, Katrivanou A, Gourzis P, Papachatzopoulou A, Athanassiadou A, Beratis S, Collier D, Polymeropoulos MH: Mutation screening of the Wolfram syndrome gene in psychiatric patients. Mol Psychiatry. 2001, 6 (1): 39-43. 10.1038/sj.mp.4000787.View ArticlePubMedGoogle Scholar
- Colosimo A, Guida V, Rigoli L, Di Bella C, De Luca A, Briuglia S, Stuppia L, Salpietro DC, Dallapiccola B: Molecular detection of novel WFS1 mutations in patients with Wolfram syndrome by a DHPLC-based assay. Hum Mutat. 2003, 21 (6): 622-629. 10.1002/humu.10215.View ArticlePubMedGoogle Scholar
- Smith CJ, Crock PA, King BR, Meldrum CJ, Scott RJ: Phenotype-genotype correlations in a series of wolfram syndrome families. Diabetes Care. 2004, 27 (8): 2003-2009. 10.2337/diacare.27.8.2003.View ArticlePubMedGoogle Scholar
- Consortium TGP: A map of human genome variation from population-scale sequencing. Nature. 2010, 467 (7319): 1061-1073. 10.1038/nature09534.View ArticleGoogle Scholar
- Exome Variant Server. NHLBI Exome Sequencing Project (ESP), Seattle, WA, URL: http://evs.gs.washington.edu/EVS/. Accessed October 2011
- Rendtorff ND, Lodahl M, Boulahbel H, Johansen IR, Pandya A, Welch KO, Norris VW, Arnos KS, Bitner-Glindzicz M, Emery SB, et al: Identification of p.A684V missense mutation in the WFS1 gene as a frequent cause of autosomal dominant optic atrophy and hearing impairment. Am J Med Genet A. 2011, 155A (6): 1298-1313.View ArticlePubMedGoogle Scholar
- Eiberg H, Hansen L, Kjer B, Hansen T, Pedersen O, Bille M, Rosenberg T, Tranebjaerg L: Autosomal dominant optic atrophy associated with hearing impairment and impaired glucose regulation caused by a missense mutation in the WFS1 gene. J Med Genet. 2006, 43 (5): 435-440.View ArticlePubMedPubMed CentralGoogle Scholar
- Borgna-Pignatti C, Marradi P, Pinelli L, Monetti N, Patrini C: Thiamine-responsive anemia in DIDMOAD syndrome. J Pediatr. 1989, 114 (3): 405-410. 10.1016/S0022-3476(89)80558-X.View ArticlePubMedGoogle Scholar
- Lagarde WH, Underwood LE, Moats-Staats BM, Calikoglu AS: Novel mutation in the SLC19A2 gene in an African-American female with thiamine-responsive megaloblastic anemia syndrome. Am J Med Genet A. 2004, 125A (3): 299-305. 10.1002/ajmg.a.20506.View ArticlePubMedGoogle Scholar
- Rindi G, Casirola D, Poggi V, De Vizia B, Patrini C, Laforenza U: Thiamine transport by erythrocytes and ghosts in thiamine-responsive megaloblastic anaemia. J Inherit Metab Dis. 1992, 15 (2): 231-242. 10.1007/BF01799637.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2350/13/3/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.